Hodgkin Lymphoma

Although Hodgkin lymphoma is treatable, past population-based studies have reported worse survival outcomes for non-white children, adolescents, and young adults. This study, published in Cancer, analyzed the survival rates of this patient population with Hodgkin lymphoma while adjusting for sociodemographic factors and treatment.  This study relied on data from 4,807 patients with Hodgkin lymphoma younger than...

This study, published in JNCI: Journal of the National Cancer Institute, examined the impact of treatment-related morbidity on long-term, cause-specific mortality in patients with Hodgkin lymphoma. The study included 4,919 patients with Hodgkin lymphoma who were treated before age 51 between 1965 and 2000. The median follow-up was 20.2 years. The researchers used the data gathered...

Although rare, there are cases in which classic Hodgkin lymphoma (CHL) and follicular lymphoma (FL) occur simultaneously at the same site. Known as composite classic Hodgkin lymphoma and follicular lymphoma (CHLFL), this condition is rare and not well understood. This article, published in the American Journal of Clinical Pathology, examined two case studies that showed...

A retrospective analysis of patients with classic Hodgkin lymphoma (cHL) treated with PD-1 inhibitors will be presented at the 2021 ASH Annual Meeting & Exposition. This study, published in Blood, sought to determine the safety and efficacy of the COVID-19 vaccine for these patients. Specifically, with regard to safety, the study looked at the frequency of...

A retrospective analysis of overall survival for patients with Hodgkin’s Lymphoma (HL), diffuse large B-cell lymphoma (DLBCL), and primary central nervous system lymphoma (PCNS) will be presented at the 2021 ASH Annual Meeting & Exposition. This study, published in Blood, is the first large-scale population analysis on a specific state (Texas) to have examined the...

An article published in Blood Advances reviewed past and ongoing clinical trials of adoptive immunotherapy for patients with classic Hodgkin lymphoma (cHL). The article also examined current challenges and strategies specific to improving the development of CAR T-cell therapy for cHL in general and relapsed or refractory cHL in particular.  The authors gathered data from eight past...